Sanofi's big dermatology hope fails in phase III

One of the drugs Sanofi had otherwise imagined would become one of the stars in the autoimmune medication portfolio has flunked out of phase III trials as a treatment for skin disease pemfigus.
Photo: Dado Ruvic/REUTERS / X02714
Photo: Dado Ruvic/REUTERS / X02714

As things appear at the moment, Sanofi hasn't achieved its ambitions with drug rilzabrutinib that management had otherwise hoped when the French pharmaceutical company acquired the compound via its acquisition of Prinicipia Biopharma in 2020.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading